Brief: Pulse Biosciences First-In-Human Procedures With Its Novel Cellfx™ Nanosecond Pulsed Field Ablation (Nspfa™) Cardiac Catheter
20/12/2023 13:05
Dec 20 (Reuters) - Pulse Biosciences Inc PLSE.O :
* FIRST-IN-HUMAN PROCEDURES WITH ITS NOVEL CELLFX™
NANOSECOND
PULSED FIELD ABLATION (NSPFA™) CARDIAC CATHETER
Source text for Eikon: ID:nBw9sY58Sa
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsBrief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System